摘要
目的探究厄贝沙坦氢氯噻嗪片在脑梗死合并高血压患者中的治疗效果。方法选择脑梗死合并高血压患者作为研究对象,开展时间为2020年3月至2021年3月,病例数80例,随机分组,40例接受厄贝沙坦片治疗纳入对照组,40例接受厄贝沙坦氢氯噻嗪片治疗纳入观察组,比较两组患者血压水平、神经功能缺损程度以及用药不良反应。结果用药治疗前患者舒张压与收缩压水平比较,差异无统计学意义(P>0.05),治疗后患者舒张压及收缩压水平均有明显降低,且观察组舒张压、收缩压水平显著低于对照组,差异有统计学意义(P<0.05);用药前两组患者NIHSS评分比较,差异无统计学意义(P>0.05),两组患者用药后神经功能缺损程度NIHSS评分相比于用药前均有明显降低,且观察组NIHSS评分低于对照组,差异有统计学意义(P<0.05);观察组用药不良反应发生率5.00%,低于对照组用药不良反应发生率7.50%,但差异无统计学意义(P>0.05)。结论脑梗死合并高血压的临床治疗中应用厄贝沙坦氢氯噻嗪片可以有效降低患者血压水平,改善伸进功能缺损程度,且用药安全,值得应用。
Objective To investigate the therapeutic effect of irbesartan hydrochlorothiazide tablets in patients with cerebral infarction complicated with hypertension.Methods 80 cases of patients with cerebral infarction and hypertension were selected as subjects from March 2020 to March 2021.By random grouping,40 patients treated with irbesartan were included in the control group,40 patients treated with irbesartan hydrochlorothiazide tablets were included in the observation group,and the blood pressure level,the degree of neurological deficit and the adverse drug reactions were compared between the two groups.Results There was no significant difference between diastolic blood pressure and systolic blood pressure before medication,(P>0.05).After treatment,the diastolic and systolic blood pressure levels significantly decreased.The levels of diastolic and systolic blood pressure in the observation group were significantly lower than those in the control group,and the difference was statistically significant(P<0.05).Before the use of drugs,the NIHSS scores of the two groups were not significantly different,(P>0.05).Comping the two groups,the degree NIHSS neurological deficit was significantly lower than before,the NIHSS score in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse drug reactions in the observation group was 5.00%,lower than 7.50%in control group.But the difference was not statistically significant(P>0.05).Conclusion The use of irbesartan hydrochlorothiazide tablets in the clinical treatment of cerebral infarction with hypertension can effectively reduce the blood pressure level of patients,to improve the penetration defect,and it is safe,worth applying.
作者
邓旭华
DENG Xu-hua(Deqing County People's Hospital,Zhaoqing,Guangdong 526600)
出处
《智慧健康》
2021年第29期145-147,共3页
Smart Healthcare
关键词
脑梗死
高血压
厄贝沙坦氢氯噻嗪片
血压
神经功能
不良反应
Cerebral infarction
Hypertension
Irbesartan hydrochlorothiazide tablets
Blood pressure
Neurological function
Adverse reactions
